振德医疗：12月15日召开董事会会议

Group 1 - The core point of the article is that Zhend Medical (SH 603301) held its fourth fifth board meeting on December 15, 2025, to discuss the proposal for the 2026 first extraordinary shareholders' meeting [1] - Zhend Medical's revenue composition for the first half of 2025 was entirely from medical dressings, accounting for 100.0% [2] - As of the report, Zhend Medical's market capitalization was 17.6 billion yuan [2] Group 2 - The article mentions a controversy surrounding a product called "Tongyan Needle," which reportedly generated 300 million yuan in annual sales, with concerns raised about the legitimacy of several related parties [2] - There are allegations that the Qian siblings have nearly "emptied" Jiangsu Wuzhong, leading to the company's impending delisting [2]